119 related articles for article (PubMed ID: 35401748)
1. Efficacy of the Low Dose Apatinib plus Chemotherapy on Advanced Gastric Carcinoma.
Gao S; Li X; Shi W; Huo L; Liu H
J Oncol; 2022; 2022():3009494. PubMed ID: 35401748
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of the low dose apatinib plus deep hyperthermia as third-line or later treatment in HER-2 negative advanced gastric cancer.
Han G; Sun C; Cui L; Huang Y; Yu L; Liu S; Tao M
Pathol Oncol Res; 2023; 29():1611114. PubMed ID: 37465317
[No Abstract] [Full Text] [Related]
3. Efficacy and safety of intermittent versus continuous dose apatinib plus docetaxel as second-line therapy in patients with advanced gastric cancer or gastroesophageal junction adenocarcinoma: a randomized controlled study.
Yan Y; Li H; Wu S; Wang G; Luo H; Niu J; Cao L; Hu X; Xu H; Jia W; Sun Y; Yao Y; Chen W; Ke L; Hu B; Ji C; Sun Y; Chen J; Li M; He Y
Ann Transl Med; 2022 Feb; 10(4):205. PubMed ID: 35280426
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of apatinib combined with tegafur gimeracil and oteracil potassium in the second-line treatment of advanced gastric cancer.
Chen H; Xue L; Liu L; Li P
J BUON; 2021; 26(3):917-923. PubMed ID: 34268954
[TBL] [Abstract][Full Text] [Related]
5. Effect of different doses of apatinib mesylate combined with chemotherapy on advanced oral cancer.
Yan W; Yan J; Chen Y; Li Q; Guo Y
Am J Transl Res; 2021; 13(12):13902-13908. PubMed ID: 35035731
[TBL] [Abstract][Full Text] [Related]
6. Clinical Efficacy and Safety of Bevacizumab, Apatinib, and Recombinant Human Endothelial Inhibitor in the Treatment of Advanced Gastric Cancer.
Wang L; Li W; Liu YG; Zhang C; Gao WN; Gao LF
J Oncol; 2022; 2022():6189833. PubMed ID: 35251174
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of Apatinib plus S-1 Therapy in the Treatment of Advanced Gastric Cancer Patients and the Effect on the Levels of Tumor Markers and Th1 and Th2-Like Cytokines.
Gu J; Ni X; Ji J; Wei G; Shi L; Xu C
Evid Based Complement Alternat Med; 2022; 2022():8060026. PubMed ID: 35529932
[TBL] [Abstract][Full Text] [Related]
8. [Clinical study of apatinib combined with chemotherapy for advanced non-small cell lung cancer with negative driving genes].
Li YF; Jiang HY; Li Q; Zhu M; Lyu J; Zhao HY
Zhonghua Zhong Liu Za Zhi; 2019 Oct; 41(10):775-781. PubMed ID: 31648501
[No Abstract] [Full Text] [Related]
9. Observation on the Clinical Effect of Apatinib Combined with Chemotherapy in the Treatment of Advanced Non-Small Cell Lung Cancer.
Cui YJ; Liu J; Liu MM; Zhang HZ
Pak J Med Sci; 2021; 37(4):1036-1041. PubMed ID: 34290779
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of Conversion Surgery Following Apatinib Plus Paclitaxel/S1 for Advanced Gastric Cancer With Unresectable Factors: A Multicenter, Single-Arm, Phase II Trial.
Xu Z; Hu C; Yu J; Du Y; Hu P; Yu G; Hu C; Zhang Y; Mao W; Chen S; Cheng X
Front Pharmacol; 2021; 12():642511. PubMed ID: 33815124
[No Abstract] [Full Text] [Related]
11. Clinical efficacy and survival analysis of apatinib combined with docetaxel in advanced esophageal cancer.
Li J; Jia Y; Gao Y; Chang Z; Han H; Yan J; Qin Y
Onco Targets Ther; 2019; 12():2577-2583. PubMed ID: 31040700
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Apatinib Plus Vinorelbine in Patients With Wild-Type Advanced Non-Small Cell Lung Cancer After Second-Line Treatment Failure: A Nonrandomized Clinical Trial.
Zhang X; Xiong Y; Xia Q; Wu F; Liu L; Zhou Y; Zeng L; Zhou C; Xia C; Jiang W; Liao D; Xiao L; Liu L; Yang H; Guan R; Li K; Wang J; Lei G; Zhang Y; Yang N
JAMA Netw Open; 2020 Mar; 3(3):e201226. PubMed ID: 32191330
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness and safety of low-dose apatinib in advanced gastric cancer: A real-world study.
Du Y; Cao Q; Jiang C; Liang H; Ning Z; Ji C; Wang J; Zhou C; Jiang Z; Yu C; Li L; Zhao Y; Xu Y; Xu T; Hu W; Wang D; Cheng H; Wang G; Zhou J; Wang S; Zhang Y; Hu Z; Li X; Lu D; Zhang J; Xie H; Sun G
Cancer Med; 2020 Jul; 9(14):5008-5014. PubMed ID: 32441892
[TBL] [Abstract][Full Text] [Related]
14. Clinical effects of Apatinib combined with DOS neoadjuvant chemotherapy regimen in neoadjuvant chemotherapy for LAGC.
Zhou PZ; Gao L; Wu W; Hao YX
Pak J Med Sci; 2021; 37(7):1890-1895. PubMed ID: 34912413
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and prognosis analyses of apatinib combined with S-1 in third-line chemotherapy for advanced gastric cancer.
Wu Q; Fu Y; Wen W; Xi T; Zhao G
J BUON; 2020; 25(2):987-994. PubMed ID: 32521896
[TBL] [Abstract][Full Text] [Related]
16. Safety Analysis of Apatinib Combined with Chemotherapy in the Treatment of Advanced Gastric Carcinoma: A Randomised Controlled Trial.
Yuan M; Wang Z; Zhang Y; Chen L; Liu Y; Cui C; Sun B
J Oncol; 2021; 2021():5177140. PubMed ID: 34422049
[TBL] [Abstract][Full Text] [Related]
17. Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial.
Xie L; Xu J; Sun X; Guo W; Gu J; Liu K; Zheng B; Ren T; Huang Y; Tang X; Yan T; Yang R; Sun K; Shen D; Li Y
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32376724
[TBL] [Abstract][Full Text] [Related]
18. Clinical efficacy and safety of apatinib combined with S-1 in advanced esophageal squamous cell carcinoma.
Zhao J; Lei J; Yu J; Zhang C; Song X; Zhang N; Wang Y; Zhang S
Invest New Drugs; 2020 Apr; 38(2):500-506. PubMed ID: 31650447
[TBL] [Abstract][Full Text] [Related]
19. A Study Of Efficacy And Safety With Apatinib Or Apatinib Combined With Chemotherapy In Recurrent/advanced Ovarian Cancer Patients.
Yang M; Liu X; Zhang C; Liao F; Li Z; Luo X; Sun Y; Chen C
Cancer Manag Res; 2019; 11():8869-8876. PubMed ID: 31632146
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of IgG, IgM, CD4+ and CD8+ T cells during neoadjuvant chemotherapy with Tezio and Apatinib in gastric cancer patients.
Cui Z; Zhang J; Zhang J; Xu L
Cell Mol Biol (Noisy-le-grand); 2020 Jun; 66(3):113-118. PubMed ID: 32538756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
